Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy
| Autor: | W. Bierbaum, Norbert Niederle, Siegfried Seeber, M. Higi, Carl G. Schmidt |
|---|---|
| Rok vydání: | 1980 |
| Předmět: |
Male
Cancer Research Vomiting Nausea medicine.drug_class medicine.medical_treatment Antineoplastic Agents Pharmacology Refractory Neoplasms Methotrimeprazine Humans Medicine Antiemetic Ifosfamide Cisplatin Chemotherapy business.industry Cancer General Medicine medicine.disease Oncology Doxorubicin medicine.symptom business medicine.drug |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 97:81-86 |
| ISSN: | 1432-1335 0171-5216 |
| DOI: | 10.1007/bf00411281 |
| Popis: | The antiemetic quality of the orally administered phenothiazine derivative levomepromacine was studied under clinical conditions in cancer patients receiving either cisplatin alone, ifosfamide alone or adriamycincontaining combinations. Seventy of 113 evaluable patients (62%)-all refractory to conventional antiemetics-were fully protected from nausea and vomiting when levomepromacine (2×8–15 mg) was administered in two steps (12 h and 1 h before the cytotoxic agents). Another 34% of all patients showed considerable improvement with respect to gastrointestinal side effects. The most pronounced effect with levomepromacine was seen in patients treated with a 20 mg/m2 daily×5 schedule of cisplatin but complete or partial relief was also seen with high single cisplatin doses of 50–100 mg/m2. In addition, the antiemetic showed effectiveness against nausea and vomiting induced by other agents, such as adriamycin or isofosfamide. Although a final evaluation of the antiemetic effect of levomepromacine will have to be based on a double-blind study, these initial observations have already been of great value for many patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink